To include your compound in the COVID-19 Resource Center, submit it here.

Emerging Companies

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make...

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

Inmagene emerged from stealth with a clinical psoriasis program from Swedish biotech Affibody. Inmagene emerged from stealth last week with plans to expand the biologics markets in China, starting with a Phase II psoriasis program...

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

A team of gene therapy veterans from the likes of Sangamo, Spark and AveXis have debuted Kriya with an untranched $80.5 million series A round to bring gene therapies to patients with prevalent and severe...

QurAlis taking three ALS programs toward clinic with $42M series A

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis...

Dyno taking partner-heavy strategy with next-generation gene therapy vectors

After two years in stealth mode, modestly-funded Dyno believes its synthetic capsid engineering platform will be best used by partners to feed their gene therapy pipelines with optimized candidates -- including two biopharmas that have...

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...

Rome: tackling repeat DNA for cancer, autoimmunity

GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer. Rome Therapeutics Inc. launched...

Taysha: Applying AAV9 across the CNS

Taysha launched with a $30 million seed round and a team of former AveXis leaders ready to parlay their experience with Zolgensma into a broad pipeline of AAV9-based gene therapies for other CNS disorders. The...

Bugworks: breaking the U.S.-centric antimicrobial mold

With offices in India and the U.S., Bugworks is taking a global approach to antimicrobial drug development that relies equally on grants and venture capital. The company, which raised $7.5 million in venture funds last...

FoRx: A broader look at DNA damage repair

University of Geneva spinout FoRx debuted this week with €10 million in seed funding, a trio of strategic investors, and a new approach to synthetic lethality that could expand the cancer-killing mechanism to a broad...

Rgenta: enhancing interactions between RNA and RNA-binding proteins

Rgenta launched this month with a $20 million seed round to develop compounds that enhance regulatory RNA-protein interactions. The company is disease-agnostic and using amenability to small molecule intervention to guide target selection. Co-founder, President...

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

Third Rock Ventures led a syndicate that invested $86 million in a series A round for MOMA Therapeutics, a newly launched start-up that will seek to interrogate a class of "molecular machines" that drive cellular...

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...